Glimisave Max 3 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3 mg and Metformin 750 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glycemic control. This combination provides complementary mechanisms of action, making it effective for patients inadequately controlled on monotherapy. Glimisave Max 3 Tablet PR is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications. It is particularly beneficial for patients with insulin resistance and beta-cell dysfunction. The prolonged-release formulation allows for sustained drug release, improving patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea or diarrhea, and rarely, lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Glimisave Max 3 Tablet PR should be used cautiously in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Consultation with a healthcare provider is essential to determine appropriate dosing and to manage potential drug interactions.